Company Description
DiamiR Biosciences is a molecular diagnostics company initially focused on the development and commercialization of innovative blood-based tests for detection and monitoring of Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative diseases (NDs).
The proprietary technology we developed is based on quantitative analysis of “organ-enriched”, i.e. present at higher concentration in specific organs or tissues, microRNAs in plasma.
We believe that the technology can also be applied to disease areas beyond NDs. These projects include a test for a rare neurological and developmental disorder Rett syndrome which is currently being clinically validated, and cancer and inflammatory disorders, where the Company’s work is at an early stage.
The tests being developed at the Company are currently not commercially available.
| Country | United States |
| Founded | 2009 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Alidad Mireskandari |
Contact Details
Address: 11 Deer Park Drive, Suite 102G Monmouth Junction, NJ 08852 United States | |
| Phone | 732-823-1143 |
| Website | diamirbio.com |
Stock Details
| Ticker Symbol | DIMR |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001621459 |
| Employer ID | 47-3736261 |
| SIC Code | 3829 |
Key Executives
| Name | Position |
|---|---|
| Alidad Mireskandari | Chief Executive Officer, Director |
| Kira S. Sheinerman | Chairperson of the Board of Directors, Secretary and Treasurer |
| Samuil Umansky | Chief Scientific Officer |
| Gary Anthony | Chief Financial Officer |
| Chris Bernard | Director |
| Laura A. Philips | Director |
| Eugene W. Williams | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 1, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 16, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 28, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 20, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 5, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 9, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 4, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 22, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Oct 13, 2023 | DRS | [Cover] Draft Registration Statement |